Notably, two studies controlled the dosage of GLP-1R agonists at a level that would not affect the blood glucose of in vivo DM models, and these two studies demonstrated that the neuroprotective effects of GLP-1R agonists are independent of their blood glucose-lowering effects
In the first year of study 38.7 % (n=24) individuals in semaglutide arm continued 14 mg dose and the remaining had dose reduced to 7 mg due to GI discomfort
Understanding the legal implications of using this medication is crucial for patients and healthcare providers alike
For billing guidance specific to your practice, consult our certified medical billing specialist at Hello MDs
A 12-month NAFLD trial reported about 32% liver-fat reduction versus placebo
Key Findings 93.4% of patients would get bariatric surgery again 51.4% of patients would consider using GLP-1 drugs again 57.1% of GLP-1 patients reported losing at least 20 pounds 98.1% of bariatric surgery patients reported losing at least 20 pounds Median weight loss for bariatric surgery patients was 100 pounds, as opposed to 20 for GLP-1s Average weight loss for bariatric surgery was reported to be 101.2, as opposed to 24.9 for GLP-1 users 93.4% of Patients Would Get Bariatric Surgery Again Out of all patients surveyed, 93.4% said they would get bariatric surgery again
